Muna Bhanji - Net Worth and Insider Trading

Muna Bhanji Net Worth

The estimated net worth of Muna Bhanji is at least $2 Million dollars as of 2024-11-28. Muna Bhanji is the Director of Veracyte Inc and owns about 23,105 shares of Veracyte Inc (VCYT) stock worth over $990,973. Muna Bhanji is the Director of Cytokinetics Inc and owns about 17,631 shares of Cytokinetics Inc (CYTK) stock worth over $920,691. Muna Bhanji is also the Director of Intellia Therapeutics Inc and owns about 11,996 shares of Intellia Therapeutics Inc (NTLA) stock worth over $182,459. Details can be seen in Muna Bhanji's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Muna Bhanji has not made any transactions after 2024-06-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Muna Bhanji

To

Muna Bhanji Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Muna Bhanji owns 4 companies in total, including Cytokinetics Inc (CYTK) , Veracyte Inc (VCYT) , and Ardelyx Inc (ARDX) among others .

Click here to see the complete history of Muna Bhanji’s form 4 insider trades.

Insider Ownership Summary of Muna Bhanji

Ticker Comapny Transaction Date Type of Owner
CYTK Cytokinetics Inc 2024-06-10 director
VCYT Veracyte Inc 2024-06-10 director
ARDX Ardelyx Inc 2021-03-11 director
LIMIT LIMIT 2023-10-31 director

Muna Bhanji Latest Holdings Summary

Muna Bhanji currently owns a total of 3 stocks. Among these stocks, Muna Bhanji owns 23,105 shares of Veracyte Inc (VCYT) as of June 10, 2024, with a value of $990,973 and a weighting of 47.32%. Muna Bhanji owns 17,631 shares of Cytokinetics Inc (CYTK) as of June 10, 2024, with a value of $920,691 and a weighting of 43.97%. Muna Bhanji also owns 11,996 shares of Intellia Therapeutics Inc (NTLA) as of October 31, 2023, with a value of $182,459 and a weighting of 8.71%.

Latest Holdings of Muna Bhanji

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
VCYT Veracyte Inc 2024-06-10 23,105 42.89 990,973
CYTK Cytokinetics Inc 2024-06-10 17,631 52.22 920,691
NTLA Intellia Therapeutics Inc 2023-10-31 11,996 15.21 182,459

Holding Weightings of Muna Bhanji


Muna Bhanji Form 4 Trading Tracker

According to the SEC Form 4 filings, Muna Bhanji has made a total of 4 transactions in Veracyte Inc (VCYT) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Veracyte Inc is the sale of 3,870 shares on June 10, 2024, which brought Muna Bhanji around $78,638.

According to the SEC Form 4 filings, Muna Bhanji has made a total of 2 transactions in Cytokinetics Inc (CYTK) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Cytokinetics Inc is the sale of 2,000 shares on June 10, 2024, which brought Muna Bhanji around $104,140.

According to the SEC Form 4 filings, Muna Bhanji has made a total of 3 transactions in Intellia Therapeutics Inc (NTLA) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Intellia Therapeutics Inc is the sale of 265 shares on October 31, 2023, which brought Muna Bhanji around $6,334.

Insider Trading History of Muna Bhanji

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Muna Bhanji Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Muna Bhanji Ownership Network

Ownership Network List of Muna Bhanji

No Data

Ownership Network Relation of Muna Bhanji

Insider Network Chart

Muna Bhanji Owned Company Details

What does Cytokinetics Inc do?

Who are the key executives at Cytokinetics Inc?

Muna Bhanji is the director of Cytokinetics Inc. Other key executives at Cytokinetics Inc include SVP Research & Early Dev Fady Ibraham Malik , EVP & Corp. Development & CBO Robert I Blum , and VP & Chief Accounting Officer Robert Wong .

Cytokinetics Inc (CYTK) Insider Trades Summary

Over the past 18 months, Muna Bhanji made 2 insider transaction in Cytokinetics Inc (CYTK) with a net sale of 4,000. Other recent insider transactions involving Cytokinetics Inc (CYTK) include a net sale of 343,500 shares made by Robert I Blum , a net sale of 205,949 shares made by Fady Ibraham Malik , and a net sale of 40,000 shares made by B Lynne Parshall .

In summary, during the past 3 months, insiders sold 90,420 shares of Cytokinetics Inc (CYTK) in total and bought 0 shares, with a net sale of 90,420 shares. During the past 18 months, 652,527 shares of Cytokinetics Inc (CYTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 652,527 shares.

Cytokinetics Inc (CYTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cytokinetics Inc Insider Transactions

No Available Data

Muna Bhanji Mailing Address

Above is the net worth, insider trading, and ownership report for Muna Bhanji. You might contact Muna Bhanji via mailing address: C/o Cytokinetics, Incorporated, 280 East Grand Avenue, South San Francisco Ca 94080.

Discussions on Muna Bhanji

No discussions yet.